SILC (S100A9 Inhibition by Low molecular weight Compounds) is a preclinical immuno-oncology project focused on S100A9 as the target molecule for treatment of cancer.

S100A9 is expressed in the tumor microenvironment and is involved in the development of cancer through recruitment and activation of specific immune cells that counteract the T-cell’s ability to attack and eradicate the tumor. S100A9 is also involved in the establishment of pre-metastatic niches and in the formation of new blood vessels, which provide nutrition and oxygen into the growing tumor. Blocking the function of S100A9 using SILC compounds could represent a new treatment alternative to help the body’s own immune system fight cancer.

S100A9 promotes tumor progression via multiple pathways. Illustration adapted from Riehl et al., Cell Communic Signal, 2009

Lead compounds have been identified in a high-throughput screening program and further optimized for oral administration and tolerability.

Patent applications have been filed for the purpose of obtaining patent protection for three chemically unrelated compound groups. To date, two of the three patent families have been granted patents in Europe and in the United States.

Active Biotech is seeking a collaboration partner for the project. The right license partner is welcome to join in already at this stage to ensure that the continued development is optimized.

Targeting S100A9 in cancer